Positive phase IIb data for BAF312 (siponimod) in MS

Mayzent is an oral treatment for relapse remitting MS and active secondary progressive MS.
Post Reply
User avatar
MSUK
Family Elder
Posts: 2903
Joined: Wed Oct 14, 2009 2:00 pm
Contact:

Positive phase IIb data for BAF312 (siponimod) in MS

Post by MSUK » Fri Apr 20, 2012 2:35 am

Image

At the 64th annual meeting of the American Academy of Neurology (AAN) Novartis will present the key results from a phase II dose finding study of its investigational compound BAF312 (siponimod), a selective modulator of the S1P receptor subtypes 1 and 5 (S1P1, 5-R modulator), in MS.

This double-blind placebo-controlled study applied an innovative adaptive trial design to optimally describe the dose response relationship.

A statistically significant dose response relationship could be established....Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1397
MS-UK - http://www.ms-uk.org/

Post Reply
  • Similar Topics
    Replies
    Views
    Last post